{
  "ticker": "IMM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976933",
  "id": "02976933",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250805",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjwmmxs87bnf.pdf",
  "summary": "- **FDA Feedback**: Positive and constructive feedback from FDA on eftilagimod alfa (\"efti\") for 1L HNSCC patients with PD-L1 CPS <1.  \n- **Clinical Paths**: Potential registrational trial (randomized vs. standard-of-care) or smaller single-arm study (70-90 patients) with accelerated approval under FDA\u2019s **Project FrontRunner**.  \n- **Unmet Need**: CPS <1 patients (~20% of 1L HNSCC) lack effective non-chemotherapy options; current anti-PD-1 therapies only approved for CPS >1.  \n- **Focus Remains on TACTI-004**: Primary development priority is Phase III trial for non-small cell lung cancer (NSCLC), but HNSCC pathways under evaluation.  \n\n**No capital or trading-specific details identified.**",
  "usage": {
    "prompt_tokens": 1343,
    "completion_tokens": 177,
    "total_tokens": 1520,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T00:06:04.011100"
}